2026 CMS Skin Substitute Rule: What Every Wound Care Practice Must Know

2026 CMS Skin Substitute Rule: What Changed and What It Means

January 1, 2026 was the biggest single-day change to wound care reimbursement in a decade. CMS reclassified most skin substitute products from biologicals (paid at ASP + 6%) to incident-to supplies (paid at a flat standardized rate). The practical result: a reimbursement cut of approximately 90% on high-cost products.

Practices that did not adjust formularies and documentation protocols before January 1 are experiencing revenue shortfalls right now.

What Changed

Before 2026 (ASP methodology): Products coded individually (Q4100–Q4299), each paid at average sales price + 6%. A premium skin substitute product at $3,000 ASP generated $3,180 in reimbursement. Application codes (15271–15278) billed separately.

2026 (Incident-to flat rate): All skin substitutes — regardless of product, FDA classification, or manufacturer — paid at $127.28/cm² as incident-to supplies under the Medicare Physician Fee Schedule. Application codes still billable separately, but product reimbursement is capped.

Products exempt from the flat rate: Biological products licensed under Section 351 of the Public Health Service Act (PHS Act) continue to be paid under ASP methodology. Confirm with your product reps which specific products fall under 351 licensure vs. 510(k)/PMA/361 HCT/P classification.

The Formulary Math

At $127.28/cm² reimbursement, your product cost must be under approximately $100/cm² to preserve a margin after overhead and application time.

Product Cost/cm²	Reimbursement	Margin/cm²
$30	$127.28	$97.28
$75	$127.28	$52.28
$127	$127.28	$0.28
$200	$127.28	-$72.72
$500	$127.28	-$372.72

Every product in your formulary with a per-cm² cost above $127.28 is a financial loss under 2026 rules. This calculation must be done for every product. Products that were profitable under ASP billing may now be loss leaders.

The LCD Withdrawal: What It Does and Does Not Change

CMS also withdrew the proposed new LCD for skin substitutes before January 1, 2026. This causes confusion. To be direct:

The LCD withdrawal does NOT affect payment. The $127.28/cm² flat rate is live regardless of whether an LCD governs coverage.

The LCD withdrawal affects coverage criteria. Until a new LCD is finalized, coverage for medically necessary DFU and VLU advanced therapy continues under existing Medicare statutory requirements and general medical necessity standards — including your MAC's existing coverage framework and clinical necessity documentation requirements.

Document as thoroughly as you always did. The standard care documentation, ABI, serial measurements, and 30-day conservative treatment record remain the coverage defense regardless of LCD status.

Documentation That Protects Revenue at $127.28/cm²

At lower revenue per application, documentation quality matters more, not less. A single denied application at $127.28/cm² is a $127.28/cm² loss. Post-payment audit recovery risk on a 20-application year is significant.

Non-negotiable per application visit:

30 days prior conservative care with serial measurements documented
Area reduction calculation at week 4 showing less than 50%
Product name, Q code, lot number, expiration date in the record
Application dimensions (L×W in cm, area calculated)
ABI on file within 90 days
Offloading for DFU or compression compliance for VLU documented
Mandatory photographs — CMS now requires photographic documentation at each application

The Revenue Model Under 2026 Rules

At $127.28/cm², a 5 cm² DFU application generates $636.40 for product plus the application code (15275: ~$185). Total per-application revenue: approximately $821.

Under 2025 ASP rules with a high-cost product, the same application might have generated $3,000–$5,000+. The revenue model for practices heavily weighted toward advanced therapies has fundamentally changed.

Where revenue holds: Debridement, E/M, compression application. The practices doing weekly debridement and E/M visits on complex wounds — before, during, and after any advanced therapy episodes — are more insulated from the advanced therapy reimbursement cut.